Table 1 Induction and maintenance doses
From: Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
First induction dose | Second induction dose | Maintenance dose | |
|---|---|---|---|
Ustekinumab | Weight based (IV): < 55 kg: 260 mg week 0 > 55 and < 85 kg: 390 mg week 0 > 85 kg: 520 mg week 0, response assessed at week 6 | Additional 90 mg dose week 8, response assessed week 16 (SC) | 90 mg every 12 weeks (SC) |
Adalimumab | 160 mg at week 0, 80 mg at week 2 (SC), response assessed at week 4 | 40 mg dose through week 12 (SC) | 40 mg every 2 weeks (SC) |
Vedolizumab | 300 mg at weeks 0, 2 and 6 (IV), response assessed at week 10 | Additional dose week 10, response assessed week 14 (IV) | 300 mg every 8 weeks (IV) |